tradingkey.logo
搜尋

Lifecore Biomedical Inc

LFCR
添加自選
5.090USD
-0.180-3.42%
收盤 07/02, 13:00美東報價延遲15分鐘
190.76M總市值
虧損本益比TTM

Lifecore Biomedical Inc

5.090
-0.180-3.42%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-3.42%

5天

-1.55%

1月

-12.09%

6月

-34.24%

今年開始到現在

-37.78%

1年

-36.69%

關鍵數據
5.270今開
5.490最高
121.55K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.32%換手率
5.270昨收
5.080最低
455.30K成交額
虧損本益比靜
-6.71市淨率
0.00%股息率 TTM
-3.54%ROA
8.98052週最高
0.48量比
-44.36M淨利潤
37.48M總股本
-0.1069每股盈餘TTM
1.07Beta
-701.27%ROE
3.62552週最低
7.78%振幅
19.24%毛利率
190.76M總市值
-2.45回報/風險
3.67%風險率

TradingKey Lifecore Biomedical Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Lifecore Biomedical Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名80/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為6.83。中期看,股價處於上升通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Lifecore Biomedical Inc評分

相關信息

行業排名
80 / 157
全市場排名
187 / 4565
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Lifecore Biomedical Inc亮點

亮點風險
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
業績增長期
公司處於發展階段,最新年度總收入75.52M美元
業績轉虧
公司業績轉虧,最新年度虧損美元
估值低估
公司最新PE估值-47.61,處於3年歷史低位
機構加倉
最新機構持股30.56M股,環比增加3.27%
史蒂文·科恩持倉
明星投資者史蒂文·科恩持倉,最新持倉19.62K股

分析師目標

基於 5 分析師
買入
評級
6.833
目標均價
+29.66%
漲幅空間

Lifecore Biomedical Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Lifecore Biomedical Inc簡介

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
公司代碼LFCR
公司Lifecore Biomedical Inc
CEOJosephs (Paul)
網址https://www.lifecore.com/

常見問題

Lifecore Biomedical Inc(LFCR)的當前股價是多少?

Lifecore Biomedical Inc(LFCR)的當前股價是 5.09。

Lifecore Biomedical Inc 的股票代碼是什麼?

Lifecore Biomedical Inc的股票代碼是LFCR。

Lifecore Biomedical Inc股票的52週最高點是多少?

Lifecore Biomedical Inc股票的52週最高點是8.98。

Lifecore Biomedical Inc股票的52週最低點是多少?

Lifecore Biomedical Inc股票的52週最低點是3.62。

Lifecore Biomedical Inc的市值是多少?

Lifecore Biomedical Inc的市值是190.76M。

現在Lifecore Biomedical Inc(LFCR)的股票是買入、持有還是賣出?

根據分析師評級,Lifecore Biomedical Inc(LFCR)的總體評級為買入,目標價格為6.83。

Lifecore Biomedical Inc(LFCR)股票的每股收益(EPS TTM)是多少

Lifecore Biomedical Inc(LFCR)股票的每股收益(EPS TTM)是-0.54。